Partnership29 Apr 2026, 09:32 am
OneSource's Partner Dr. Reddy's Gets Health Canada Nod for Generic Semaglutide
AI Summary
OneSource Specialty Pharma Limited announced that its partner, Dr. Reddy’s Laboratories Ltd., has received Health Canada approval for Semaglutide Injection, a generic version of Ozempic®. OneSource serves as the CDMO partner for this program, providing scale-up and commercial manufacturing support from its US-FDA approved facility in Bengaluru. This approval is expected to strengthen the collaboration between Dr. Reddy’s expertise in peptide development and OneSource’s CDMO capabilities, ensuring reliable and scalable commercial supply.
Key Highlights
- Dr. Reddy's received Health Canada approval for generic Semaglutide.
- OneSource is the CDMO partner for scale-up and manufacturing.
- Supply will be from OneSource's US-FDA approved Bengaluru facility.
- Approval strengthens the Dr. Reddy's and OneSource collaboration.